FDA Approves First Kidney Drug for Type 1 Diabetes in 30 Years

For the first time in 30 years, people living with both type 1 diabetes and chronic kidney disease have a new treatment option that could save their lives.

The FDA approved Bayer's drug Kerendia this month, marking a historic breakthrough for a patient population that's watched medical advances pass them by for decades. The treatment reduces protein levels in urine, a key marker that predicts whether someone will progress to kidney failure.

Between 20 and 30 percent of Americans with type 1 diabetes also develop chronic kidney disease. That's tens of thousands of people facing a terrifying reality where their kidneys slowly stop working, leaving dialysis or transplant as their only options.

Kerendia works by targeting a specific pathway in the kidneys that becomes damaged in diabetes. By reducing the protein albumin that leaks into urine, the drug helps preserve kidney function and slows the march toward end-stage disease.

The FDA granted Priority Review for Kerendia, recognizing the urgent unmet need in this community. While people with type 2 diabetes have seen multiple new kidney treatments emerge in recent years, those with type 1 have been left waiting and hoping.

The Ripple Effect

This approval means more than just one new drug on pharmacy shelves. It signals renewed attention to a patient population that's felt forgotten by the medical research community.

For younger patients especially, many diagnosed with type 1 diabetes in childhood, kidney complications represent one of the most feared long-term consequences. Preventing or delaying kidney failure doesn't just extend lives. It preserves quality of life, keeping people off dialysis machines and active in their families and careers.

The treatment also offers hope to the thousands currently watching their kidney function decline without options. Early intervention could prevent many from ever reaching that critical point where a transplant becomes necessary.

Doctors treating this population now have a concrete tool to offer patients beyond just managing blood sugar and blood pressure. That shift from helplessly monitoring decline to actively fighting it changes the entire conversation around long-term diabetes care.

After 30 years of waiting, progress has finally arrived for a community that refused to give up hope.